Taysha Gene Therapies (TSHA) Making Progress on Crucial Rett Syndrome Treatment

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the best multibagger penny stocks to invest in. On March 25, Cantor Fitzgerald reiterated an Overweight rating on Taysha Gene Therapies (NASDAQ:TSHA) with a $19 price target.

Taysha Gene Therapies, Inc. (TSHA) Making Progress on Crucial Rett Syndrome Treatment

Pressmaster/Shutterstock.com

The positive stance is in response to the company making significant progress on the development of TSHA-102, an investigational gene transfer therapy in evaluation for Rett syndrome. Chief Executive Officer Sean Noland has already confirmed they are bolstering commercial-readiness efforts ahead of potential registration.

Taysha Gene Therapies has also received FDA clearance to initiate the ASPIRE trial in 3 patients to support a potential broad label in the second quarter. The milestone follows a favorable tolerability profile, continued patient enrollment, and a well-defined regulatory trajectory.

Amid TSHA-102 development progress, Taysha Gene Therapies reported a net loss of $109 million, or $0.34 per share, for the year ended December 31, 2025. It was a significant increase from a net loss of $89.3 million, or $0.36 a share, for the year ended 2024. The wider-than-expected net loss was due to an increase in research and development expenses, which came in at $86.4 million, up from $66 million in 2024.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for severe monogenic central nervous system diseases. Their lead candidate, TSHA-102, uses miRNA-regulatory technology to treat Rett syndrome, aiming to address the disease’s underlying genetic cause.

While we acknowledge the risk and potential of TSHA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TSHA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Motley Fool’s 10 High-Growth Stock Picks and 8 Best Blue Chip AI Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.